Compare CLAR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | BNR |
|---|---|---|
| Founded | 1957 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.6M | 141.5M |
| IPO Year | 1998 | 2019 |
| Metric | CLAR | BNR |
|---|---|---|
| Price | $5.24 | $13.00 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 295.9K | 23.4K |
| Earning Date | 11-05-2026 | 11-23-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | ★ 11.68 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $228,000.00 | N/A |
| Revenue This Year | $1.01 | $101.46 |
| Revenue Next Year | $2.97 | $14.81 |
| P/E Ratio | $44.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.53 | $6.79 |
| 52 Week High | $5.32 | $41.72 |
| Indicator | CLAR | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 79.14 | 51.21 |
| Support Level | $2.63 | $9.12 |
| Resistance Level | N/A | $19.10 |
| Average True Range (ATR) | 0.27 | 1.26 |
| MACD | 0.11 | 0.16 |
| Stochastic Oscillator | 91.29 | 88.67 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and U.S.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.